• safety lab tests of various testosterone/dutasteride formulations, [ Time Frame: days 1, 2, 3, 19, 20, 21 & 26-31. ]
• lab tests for additional pharmacokinetic parameters for testosterone & dutasteride, [ Time Frame: days 1, 2, 3, 19, 20, 21 & 26-31. ]

• safety lab tests of various testosterone/dutasteride formulations, days 1, 2, 3, 19, 20, 21 & 26-31.
• lab tests for additional pharmacokinetic parameters for testosterone & dutasteride, days 1, 2, 3, 19, 20, 21 & 26-31.

The combination of testosterone and dutasteride is intended for use in hypogonadal men. This study will evaluate the bioavailability and pharmacokinetics of various doses of testosterone administered with and without dutasteride

• Drug: Nanomilled testosterone
• Drug: commercially available dutasteride
• Drug: Nanomilled dutasteride

Inclusion criteria:

• Are healthy.
• Have a BMI within range of 19-32 kg/m2.
• Have not taken dutasteride for one year, or finasteride for the past 3 months.
• Have a screening PSA < 2.0ng/mL.

Exclusion criteria:

• Have had or have breast or prostate cancer, sleep apnea, psychiatric illness, or any other clinically significant current condition.
• Have a trigliceride level =500mg/dL.
• Have abnormal thyroid or hormone levels.
• Would donate more than 500 ML of blood over a 2 month period.
• Physician does not think it is a good idea for you to participate in the trial.
• Are unwilling to abstain from alcohol during the study.
• Have a positive urine drug screen test.
• Plan to change your smoking habits during the course of the trial.
• Have Hepatitis C, Hepatitis B, or HIV.
• Have a lab or ECG abnormality.
• Have high or low blood pressure.
• Have used of any investigational drug or device during the study or within 30 days prior to 1st dosing of study medication.